Deerfield Management Company, L.P. (Series C) Intra Cellular Therapies, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $134,936 - $214,321	2,910 New	2,910 $208,000
Q1 2023 May 15, 2023	BUY	$43.8 - $56.99 $32.1 Million - $41.8 Million	734,000 New	734,000 $39.7 Million
Q4 2017 Feb 14, 2018	SELL	$14.27 - $16.79 $1.69 Million - $1.98 Million	-118,116 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$10.77 - $22.1 $1.27 Million - $2.61 Million	118,116	118,116 $1.86 Million

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

Vanguard Group Inc Valley Forge, PA

9.63M
Shares

$800 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.32M
Shares

$525 Million
0.01% of portfolio
Jpmorgan Chase & CO New York, NY

5.29M
Shares

$439 Million
0.03% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

3.85M
Shares

$320 Million
1.4% of portfolio
Avoro Capital Advisors LLC New York, NY

3.05M
Shares

$253 Million
3.36% of portfolio

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account